[Gene therapy for relapsed breast cancer].
Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.
Takahashi
Shunji
S
Department of Clinical Chemotherapy and Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Sugimoto
Yoshikazu
Y
D001943:Breast Neoplasms / Q000628:therapy*; D016207:Cytokines / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D019450:Genes, MDR / Q000235:genetics; D041722:Genes, Transgenic, Suicide / Q000235:genetics; D016762:Genes, fos / Q000235:genetics; D016259:Genes, myc / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics; D007378:Interleukins / Q000235:genetics; D012008:Recurrence; D000099180:Interleukin-24
D016207:Cytokines; D007376:Interleukin-2; D007378:Interleukins; D000099180:Interleukin-24